Last reviewed · How we verify
Dimemorphan (DIMEMORFAN)
Dimemorphan (generic name: DIMEMORFAN) is a dimemorfan drug. It is currently in Phase 2 development.
Dimemorfan works by activating opioid receptors in the brain to reduce pain perception.
Dimemorfan, a small molecule drug in the dimemorfan class, is a centrally acting analgesic with an unknown target. Its mechanism of action is not well-documented, and it has not been approved by the FDA for any indications. The current owner of dimemorfan is unknown, and its commercial status is unclear. Further research is needed to fully understand its pharmacological properties and potential clinical applications.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | DIMEMORFAN |
|---|---|
| Drug class | dimemorfan |
| Target | Sigma non-opioid intracellular receptor 1 |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | Phase 2 |
Mechanism of action
Imagine your brain has a volume control for pain. Dimemorfan turns down this volume by activating special receptors that help block pain signals. This can provide relief from discomfort without the need for other medications.
Approved indications
Common side effects
- Interstitial lung disease
- Hepatic function abnormal
Key clinical trials
- Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas (PHASE1)
- Effects of Dehydration on Motor Skills, Attention, and Performance in Adolescent Football Players (NA)
- Diltiazem in Jervell and Lange-Nielsen Syndrome (PHASE4)
- Effect of Preoperative Cold Therapy on Early Postoperative Outcomes in Total Knee Arthroplasty (NA)
- Hilotherapy vs. Kinesio Taping in Orthognathic Surgery Recovery (NA)
- Japanese Coronary Intervention Using Drug Eluting and Perfusion Therapy for Left Main Disease (JDEPTH-LM Registry)
- Vocabulary Intervention for Late Talkers (NA)
- Intranasal Oxytocin as Enhancer of Psychotherapy Outcomes in Severe Mental Illness (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dimemorphan CI brief — competitive landscape report
- Dimemorphan updates RSS · CI watch RSS
Frequently asked questions about Dimemorphan
What is Dimemorphan?
How does Dimemorphan work?
What is the generic name of Dimemorphan?
What drug class is Dimemorphan in?
What development phase is Dimemorphan in?
What are the side effects of Dimemorphan?
What does Dimemorphan target?
Related
- Drug class: All dimemorfan drugs
- Target: All drugs targeting Sigma non-opioid intracellular receptor 1
- Therapeutic area: All drugs in Pain
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing